A Study Of Corticosteroid On Postoperative Pain After Ureteroscopy For Urinary Calculi
NCT ID: NCT07223580
Last Updated: 2026-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE4
90 participants
INTERVENTIONAL
2026-01-23
2027-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Ureteral Stent and Sheaths Size on Post-Operative Pain
NCT06979583
Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal
NCT04112160
Is Prophylactic Antibiotics Necessary In Otherwise Healthy Adult Patients Undergoing Ureteroscopic Procedures for Ureteral Stones?
NCT02635490
Local Anaesthetic and Steroid in the Ureter
NCT03296189
Intraureteral Lidocaine for Post-Ureteroscopy Pain
NCT01450566
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard of care plus Corticosteroid
Participants will receive standard of care postoperative ureteroscopy medication, with the addition of prednisone 25 mg.
Corticosteroid
In addition to the standard of care postoperative ureteroscopy medication, participants will be given prednisone 25 mg orally, once a day for 5 days post-surgery.
Standard of Care
Participants will receive standard of care postoperative ureteroscopy medication, with the addition of a placebo pill.
Placebo
In addition to the standard of care postoperative ureteroscopy medication, participants will be given a placebo pill orally, once a day for 5 days post-surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Corticosteroid
In addition to the standard of care postoperative ureteroscopy medication, participants will be given prednisone 25 mg orally, once a day for 5 days post-surgery.
Placebo
In addition to the standard of care postoperative ureteroscopy medication, participants will be given a placebo pill orally, once a day for 5 days post-surgery.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 years or older
* Patients of either gender
* Patients of all ethnic backgrounds
* Cable of giving informed consent
* Capable and willing to fulfill the requirements of the study.
Exclusion Criteria
* Chronic use of opioids or other pain medication (\>12 weeks)
* Known allergies to corticosteroids.
* Known or suspected pregnancy
* Inability to give informed consent or unable to meet requirements of the study for any reason.
* Bilateral ureteroscopy
* Current Corticosteroid Use
* Diabetic patients who are insulin dependent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Karen L. Stern
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Karen L. Stern, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Rev V. Vilasan Shylaja
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Rev V. Vilasan Shylaja
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
25-003416
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.